Introduction
The intravascular administration of iodinated contrast media remains a common cause of acute kidney injury (AKI) [1, 2] . Past research has demonstrated that contrastinduced AKI (CIAKI) is associated with increased healthresource utilization, prolonged hospital stay, increased in-hospital and long-term mortality, and an acceleration in the rate of progression of chronic kidney disease (CKD) [3] [4] [5] [6] [7] [8] [9] . Three factors suggest that the incidence of CIAKI is likely to increase in the future. First, CKD, which is a principal risk factor for CIAKI, affects as many as 13 million Americans and is likely to continue to grow in prevalence [10] . Second, diabetes mellitus, which amplifies the risk for CIAKI in patients with underlying CKD, is also increasing in prevalence. Third, patients with advanced CKD have been shown to be at risk for nephrogenic systemic fibrosis, a potentially debilitating disorder that is associated with the administration of gadolinium-based contrast agents [11] . As a result, many patients with CKD, who in the past years would have undergone contrast-enhanced magnetic resonance angiography, are now likely to undergo conventional angiography with iodinated contrast, increasing the number of patients at risk for CIAKI.
Multiple interventions have been investigated for their capacity to prevent CIAKI, yet few have conclusively demonstrated effectiveness. The following review discusses the principal risk factors for CIAKI and the current evidence basis related to interventions for the prevention of this iatrogenic condition with a focus on the most recent data.
In addition, the risk for CIAKI is greater following intraarterial contrast administration than intravenous administration. Recognition of these major risk factors has facilitated the identification of patients at increased risk for CIAKI and has helped inform research efforts to identify the effectiveness of interventions for the prevention of this condition.
Prevention of contrast-induced acute kidney injury
Whereas the treatment of established CIAKI is limited to supportive care and dialysis, the renal injury resulting from iodinated contrast exposure is potentially preventable. Procedures that utilize intravascular contrast, such as coronary and noncoronary angiograms, are commonly scheduled in advance, providing sufficient time to identify patients at increased risk and implement preventive measures. Efforts to find effective preventive interventions for CIAKI have focused on four principal strategies: administration of less nephrotoxic contrast agents; provision of preemptive renal replacement therapy to remove contrast from the circulation; utilization of pharmacologic agents to counteract the nephrotoxic effects of contrast media; and expansion of the intravascular space and enhanced diuresis with intravenous (i.v.) fluids.
Type of contrast agent
Iodinated contrast agents used for clinical imaging are categorized as either ionic or nonionic, and have variable osmolalities compared with plasma. The osmolality of conventional, high-osmolal contrast is in the range of 1500-1800 mOsm/kg. 'Low'-osmolal agents were named as such because their osmolalities are less than those of high-osmolal contrast agents. However, low-osmolal contrast agents are still hyperosmolal (600-850 mOsm/kg) compared with plasma. In a large randomized controlled trial of 1196 patients conducted over a decade ago, Rudnick et al. [13] demonstrated a reduction in the incidence of CIAKI with the use of iohexol, a low-osmolal agent, compared with diatrizoate, a high-osmolal contrast medium, in patients with pre-existent renal insufficiency, independent of the presence of diabetes mellitus.
More recent studies have focused on the comparative nephrotoxicity of iodixanol, which is iso-osmolal (290 mOsm/kg) to plasma, and various low-osmolal contrast media. Although a series of randomized trials over the past decade have suggested a lower incidence of CIAKI with iodixanol in high-risk patients, other clinical trials were unable to confirm the presence of such a benefit [17] [18] [19] [20] [21] [22] . Meta-analyses and systematic reviews of these divergent results have also yielded conflicting findings on the relative nephrotoxicity of iodixanol and low-osmolal contrast agents [23] [24] [25] .
Over the past 12 months, the results of at least four clinical trials that compared iodixanol to low-osmolal contrast agents have been published. Wessely et al. [26] randomized 324 patients with CKD undergoing coronary angiography with percutaneous coronary intervention (PCI) to receive either iodixanol or the lowosmolal agent iomeprol. The primary endpoint, which was defined as the maximal increase in serum creatinine (SCr) during the hospitalization, was not different in the two groups (0.19 AE 0.4 mg/dl with iodixanol vs. 0.21 AE 0.34 mg/l with iomeprol; P ¼ 0.53). Similarly, rates of CIAKI were not different between the two groups (22.2% with iodixanol vs. 27.8% with iomeprol; P ¼ 0.25). In a smaller study, Chuang and colleagues [27] randomized 50 patients undergoing intravenous pyelography to receive iodixanol or iohexol and found no difference in the incidence of CIAKI between the two groups (4% in each). However, this study was limited by a very small number of patients, many of whom had relatively preserved kidney function at baseline. Mehran et al. [28] reported the results of the ICON study -a randomized, multicenter trial comparing iodixanol to ioxaglate in 146 patients with moderate CKD undergoing coronary angiography. The primary study endpoint, defined by the median peak increase in serum creatinine through day 3 following angiography, did not differ between the two groups (0.09 mg/dl with iodixanol vs. 0.15 mg/dl with ioxaglate; P ¼ 0.07). Whereas there were slightly lower rates of CIAKI among patients who received iodixanol, these differences did not meet the level of statistical significance. Most recently, Laskey and colleagues [29] reported the results of a randomized clinical trial that compared iodixanol to iopamidol in 418 diabetic patients with CKD undergoing coronary procedures. The proportion of patients who developed CIAKI was similar for both contrast agents (11.2% with iodixanol vs. 9.8% with iopamidol; P ¼ 0.7).
In the most recent meta-analysis, which included 16 trials encompassing 2763 patients, Reed and colleagues [30] compared iodixanol to several low-osmolal contrast agents. They found no difference in the incidence of CIAKI when they compared iodixanol to all low-osmolal contrast agents considered collectively. However, iodixanol was associated with a lower incidence of CIAKI compared with ioxaglate and iohexol, but not when compared with other low-osmolal agents. Collectively, these past and most recent studies suggest a lower incidence of CIAKI with the use of iodixanol compared with specific low-osmolal agents, namely iohexol and possibly ioxaglate, with no discernible difference when iodixanol is compared with iopamidol. However, the small numbers of patients included in past trials, coupled with the lack of data on the relative effects of iso-osmolal and low-osmolal contrast agents on serious, adverse, patient-centered outcomes are important limitations to these studies. On the basis of these data, guidelines from the American College of Cardiology/American Heart Association recommend the use of iso-osmolal contrast or low-osmolal contrast other than iohexol and ioxaglate in patients with CKD undergoing angiography [31] .
Renal replacement therapy
The use of renal replacement therapy to prevent CIAKI is predicated on the premise that rapid removal of iodinated radiocontrast material from the circulation, limiting the filtered load at the glomerulus, will decrease the risk of renal injury. However, in a series of studies that have examined the use of conventional hemodialysis following the administration of radiocontrast, no beneficial outcomes were seen [32] [33] [34] [35] [36] . In addition, there was a trend toward an increased need for therapeutic hemodialysis as well as a higher incidence of renal failure in certain studies [32, 34, 35, 37, 38] .
There have also been studies of continuous renal replacement therapies for prevention of CIAKI. Marenzi et al. [39] compared continuous hemofiltration initiated 4-8 h prior to and continued for 18-24 h following coronary angiography to volume expansion with i.v. isotonic saline for the prevention of CIAKI, as defined by a more than 25% increase in the SCr during the hospitalization. Five per cent of the patients in the hemofiltration group demonstrated this change in SCr compared with 50% of the patients in the i.v. isotonic saline group (P < 0.001). However, because continuous hemofiltration directly lowers SCr, the use of changes in its concentration as the primary study endpoint, as a surrogate for measured change in kidney function, is of questionable validity.
The observed difference in the proportion of patients sustaining a more than 25% increase in SCr primarily reflects the direct decrease in SCr by the intervention in patients treated with hemofiltration.
Cruz et al. [40] conducted a meta-analysis of blood purification therapies for the prevention of CIAKI. Considering data from eight clinical trials, six of which assessed hemodialysis and two of which assessed continuous renal replacement therapy, the authors found that renal replacement therapy did not reduce the incidence of CIAKI compared with routine preventive care [40] . Moreover, there was considerable intertrial heterogeneity. In sensitivity analyses that included only those studies of hemodialysis, intertrial heterogeneity was nonstatistically significant, yet there was a trend toward greater risk for CIAKI with hemodialysis compared with standard preventive care. In a recent trial, Holscher et al. Thus, it appears that the use of prophylactic hemodialysis is not only of no benefit, but associated with potential harm. Whereas past studies have not demonstrated harm with prophylactic hemofiltration, this therapy is associated with known risks related to catheter insertion and infection, as well as significant costs. Therefore, we cannot recommend prophylactic renal replacement therapy for the prevention of CIAKI.
Pharmacologic interventions
Trials of pharmacologic interventions, including furosemide, dopamine, fenoldopam, calcium channel blockers, and mannitol, have failed to demonstrate significant benefit for the prevention of CIAKI and in some cases have been associated with harm [41] [42] [43] . Findings on the benefit of natriuretic peptides, aminophylline, theophylline, statins, ascorbic acid, prostacyclin/prostaglandin analogs, and NAC are inconclusive. A series of recent trials provides additional data on the potential role of certain of these interventions.
Atrial natriuretic peptide
Morikawa and colleagues [44] recently reported the results of a single-center, unblinded, randomized clinical trial comparing the infusion of atrial natriuretic peptide (ANP) with i.v. fluids to an infusion of i.v. fluids alone among patients with CKD undergoing coronary angiography with or without angioplasty or stenting (PCI).
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ANP was administered at a dose of 0.042 mg/kg/min for 4-6 h prior to and 48 h following angiography. Of 254 patients who completed the study, decrements in estimated glomerular filtration rate (eGFR) at 24 h, 48 h, 1 week, and 1 month following angiography were slightly less among patients who received ANP. Similarly, the incidence of CIAKI, defined by an increase in SCr of at least 25%, at least 0.5 mg/dl, or both of these threshold changes was lower in patients who received ANP. Of note, ANP was also associated with a significant decrease in systolic blood pressure. There were no differences in the proportion of patients who required temporary dialysis or hospitalization for heart failure. The investigators posited that the lower dose and more sustained administration of ANP compared with prior negative trials of this agent accounted for the observed benefit [45, 46] . However, this study enrolled a relatively small number of patients and lacked power to discern the effects of ANP on serious, adverse, patient-centered outcomes. Because of the cost and risks associated with ANP infusion, large trials that are adequately powered to assess the risks and potential benefits of ANP will be required before this therapy can be recommended for routine use.
Statins
A series of studies have investigated the role of statins for the prevention of CIAKI because of their antioxidant and anti-inflammatory properties and effects on endothelial function [47] [48] [49] [50] . Preliminary retrospective and prospective observational studies suggested a benefit of statins in reducing the incidence of CIAKI. However, in a recent two-center clinical trial, Jo et al. [50] randomized 247 patients to receive four 40 mg doses of simvastatin or placebo, given every 12 h starting the evening before coronary angiography, and failed to demonstrate a benefit associated with statin therapy. Similarly, in a singlecenter trial, Toso et al. [51] randomized 304 patients with CKD undergoing coronary angiography with or without PCI to receive 80 mg of atorvastatin or placebo daily for 2 days prior to and 2 days following the procedure. CIAKI, defined as an increase in SCr at least 0.5 mg/dl within 5 days, developed in 10% of atorvastatin-treated patients and 11% in placebo-treated patients (P ¼ 0.86). No differences were seen between the groups in persistent renal injury at 30 days following angiography. Thus, data to date are insufficient to support the use of statins for the prevention of CIAKI.
Prostaglandin/prostacyclin analogs
A primary mechanism thought to be responsible for renal injury following intravascular iodinated contrast administration is vasoconstriction in the renal medulla [52, 53] . Prostaglandins (PGI 2 and PGE 2 ) have vasodilatory actions in the kidney and may attenuate the vasoconstrictive effects of iodinated contrast. This forms the basis for recommendations to discontinue nonsteroidal antiinflammatory drugs (NSAIDs), which inhibit vasodilatory prostaglandins in the kidney, prior to contrast administration, and has led to investigation of the effect of vasodilatory prostaglandin analogs for the prevention of CIAKI. Studies in animal models suggest a potential beneficial role of prostaglandins for the prevention of nephrotoxicity caused by iodinated contrast [54, 55] . Spargias and colleagues [56] conducted a randomized clinical trial in 208 patients with CKD who were undergoing coronary angiography, with or without PCI. Patients were randomized to receive iloprost, a PGI 2 analog, at a dose of 1 ng/kg per minute beginning 30-90 min prior to angiography and continued for 4 h following angiography, or placebo. The primary study endpoint was the development of CIAKI, defined by an increase in SCr of at least 0.5 mg/dl or at least 25% within 2-5 days. The investigators found a lower incidence of CIAKI in patients randomized to iloprost as compared with patients who received placebo (8 vs. 22%; P ¼ 0.005), with few adverse events. Notwithstanding the reasonably large reduction in the incidence of CIAKI, the results of this trial should be interpreted with caution. First, the study was powered based on an assumed 70% reduction in the incidence of the primary outcome with iloprost. This clinically and biologically implausible effect size accounted for the small study population and increased the risk for a type 1 error. Second, effects of iloprost on longer-term adverse outcomes were not investigated. With the potential for adverse side effects with prostaglandin analogs such as iloprost, we cannot recommend the routine use of these agents for the prevention of CIAKI until definite benefit is demonstrated in large clinical trials.
N-Acetylcysteine
The rationale for the use of NAC for the prevention of CIAKI relates to its capacity to scavenge reactive oxygen species (ROS), reduce the depletion of glutathione, and stimulate the production of vasodilatory mediators, including nitric oxide. Tepel et al. [57] first described the efficacy of NAC for the prevention of CIAKI in humans a decade ago. In this trial 83 patients undergoing computed tomography were randomized to receive 600 mg of NAC or placebo twice daily on the day prior to and the day of the procedure. Significantly fewer patients treated with NAC developed CIAKI compared with patients in the placebo arm (2 vs. 21%; P ¼ 0.01). Since the publication of this initial study, a multitude of trials evaluating NAC for the prevention of CIAKI have been published in the peer-reviewed literature and yielded highly conflicting results (Table 2 ) .
In an effort to reconcile the disparate clinical trial findings, multiple systematic reviews and meta-analyses have been performed to analyze the collective results of these studies. One of the largest and most rigorous of these analyses was performed by Kelly and colleagues [83] and included 26 trials, encompassing 3393 patients. On the basis of the pooled data, these investigators calculated a 38% reduction in the risk of CIAKI associated with NAC [relative risk (RR) ¼ 0.62; 95% confidence interval (CI) 0. 44-0.88] . Although the investigators identified study heterogeneity, they did not identify evidence of publication bias. In another recent meta-analysis of 22 trials, encompassing 2746 patients, Gonzales et al. [84] also found significant heterogeneity among the trials but were able to segregate the trials into two clusters that demonstrated minimal heterogeneity. One cluster included trials in which NAC was found to be protective, and was defined by an observed decline in SCr following contrast administration in the patients treated with NAC. In the studies included in the other cluster, there was no fall in SCr in the NAC-treated patients and no overall benefit for the prevention of CIAKI. The investigators concluded that NAC was not actually effective for the prevention of CIAKI and that the apparent benefit represented an artifactual effect on serum concentration independent of actual kidney function. Most recently, Trivedi and colleagues [85] conducted a meta-analysis of trials that utilized high-dose NAC, defined as a daily dose of more than 1200 mg or one dose of more than 600 mg within 4 h of contrast administration. Compared with controls, high-dose NAC was associated with a lower risk of CIAKI using either a fixed-effects [odds ratio (OR) 0.46, 95% CI 0.33-0.63] or a random-effects model. Their analysis found no significant heterogeneity or publication bias.
At the current time, no definitive conclusions on the effectiveness of NAC for the prevention of CIAKI can be drawn. If a beneficial effect exists, it may be related to the use of higher doses of NAC. Large clinical trials that are based on clinically plausible effect sizes and that examine serious, adverse, patient-centered outcomes are needed to better define the clinical utility of this agent. However, given the minimal cost and relative safety associated with NAC, its use in conjunction with appropriate fluid administration is not inappropriate.
Intravenous fluids
Intravascular volume expansion with i.v. fluids is believed to protect against the development of CIAKI via two mechanisms. First, expansion of the intravascular space is thought to blunt the vasoconstrictive effect of contrast on the renal medulla due to the suppression of vasopressin secretion, inhibition of the renin-angiotensin axis, and increased synthesis of vasodilatory renal Strategies for the prevention of CIAKI Weisbord and Palevsky 543 prostaglandins [86] . Second, i.v. fluids are believed to attenuate the direct toxic effect of contrast agents on tubular epithelial cells by decreasing the concentration and viscosity of contrast media in the tubular lumen as the result of volume-mediated inhibition of proximal tubular salt and water reabsorption and by decreasing contact time from the associated increase in tubular flow [86] . Participants in this study were randomized to receive either i.v. isotonic saline for 12 h prior to and 12 h following angiography or unrestricted oral fluids. The study was stopped at an interim analysis after 53 of 160 potential participants had been enrolled when the rate of CIAKI was found to be nearly 10-fold higher in the oral fluid group compared with the i.v. saline group (34.6 vs. 3.7%; P ¼ 0.005). The effect of tonicity of i.v. fluids on the development of CIAKI was assessed in a trial conducted by Mueller and colleagues [88] in which low-risk patients who were undergoing coronary angiography were randomized to peri-procedural i.v. volume expansion with either 0.45% (half-isotonic) saline or 0.9% (isotonic) saline. The overall rate of CIAKI was greater in patients who received half-isotonic saline compared with those who were administered isotonic saline (2 vs. 0.7%; P ¼ 0.04). On the basis of this study, it has generally been accepted that isotonic saline is superior to hypotonic saline for the prevention of CIAKI.
More recently, studies evaluating fluid administration for the prevention of CIAKI have focused on comparisons between isotonic sodium bicarbonate (bicarbonate) and isotonic sodium chloride (saline). The generation of ROS in the kidney following contrast administration is thought to be an important mediator of CIAKI. Moreover, chronic kidney disease, diabetes, intravascular volume depletion, and heart failure, all of which are important clinical risk factors for CIAKI, are themselves associated with enhanced ROS formation [89] [90] [91] . Intravenous sodium bicarbonate administration is hypothesized to mitigate generation of ROS following contrast administration as the result of urinary alkalinization. Over the past 5 years, 10 clinical trials comparing the development of CIAKI following the administration of either isotonic bicarbonate or isotonic saline have been published in the peerreviewed literature, 6 demonstrating a lower incidence of CIAKI with bicarbonate administration, whereas 4 showed no significant benefit (Table 3 ) [19, [92] [93] [94] [95] [96] [97] [98] [99] [100] .
The disparate results of these 10 clinical trials led to a proliferation of systematic reviews and meta-analyses comparing the effectiveness of bicarbonate and saline, 11 of which have now been published [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] . Among 544 Diagnostics and techniques At this time, data on the comparative effectiveness of bicarbonate and saline for the prevention of CIAKI are insufficient to warrant a recommendation for the routine use of a specific isotonic i.v. fluid. A large clinical trial that is appropriately powered to detect potentially subtle but clinically significant differences between these i.v. fluids in preventing not only CIAKI but also serious, adverse patient-centered outcomes is needed.
Methodological limitations to past research on the prevention of contrast-induced acute kidney injury
There are common themes to the limitations of the vast majority of trials evaluating the efficacy of interventions for the prevention of CIAKI. First, all published trials to date have been relatively small. For example, the largest study comparing bicarbonate to saline enrolled only 502 patients, whereas the largest study of NAC enrolled just 487 patients. These small sample sizes mean that the clinical effects of the interventions that the individual studies are able to detect are not likely to be biologically plausible. The risk of failing to detect smaller, yet clinically meaningful benefit is therefore substantial. Second, nearly all past studies were designed with small, shortterm changes in SCr as their primary endpoint. Whereas these changes in SCr have been used to define CIAKI, and are associated with mortality and other adverse clinical outcomes such as dialysis or persistent change in kidney function, it has not been demonstrated that prevention of these small changes in SCr results in improved patient outcomes. None of the trials to date has been designed with sufficient statistical power to detect differences in these clinically meaningful, patient-centered outcomes. Finally, many of the studies enrolled patients who were at relatively low risk for the development of CIAKI, further diminishing the likelihood that a relatively small study could detect a meaningful clinical benefit. It is with these limitations in mind that we propose recommendations for the prevention of CIAKI and serious, adverse sequelae of contrastenhanced imaging procedures (Table 4) .
Recommendations for prevention of contrastinduced acute kidney injury
The first step in the prevention of CIAKI is identifying patients at increased risk. For the majority of patients, who have no identifiable risk factors, the risk of developing CIAKI is very low and no additional periprocedural precautions are warranted. This is in contradistinction to high-risk patients, particularly those with underlying chronic kidney disease. In these patients, prophylactic interventions should be instituted to reduce the risk of renal injury.
The most effective approach to prevent CIAKI is avoidance of iodinated contrast media. The use of ultrasonography and unenhanced computed tomography may
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Specific modifiable risks for the development of CIAKI should be addressed. Overt volume depletion should be corrected in all patients prior to the administration of iodinated radiocontrast. In addition, nonselective nonsteroidal anti-inflammatory medications and selective cyclooxygenase-2 inhibitors, which inhibit vasodilatory prostaglandins, should be discontinued at least 24 h in advance of the planned procedure and avoided for 24-48 h following the procedure.
The dose of contrast should be limited to the minimum volume required to provide adequate clinical information. In addition, iso-osmolal or a nonionic, low osmolality contrast medium other than iohexol or ioxaglate should be employed. Intravenous isotonic saline or sodium bicarbonate should be administered prior to and following the administration of contrast. Although the administration of isotonic saline at a dose of 1 ml/kg/h for 12 h preceding and 12 h following the administration of iodinated contrast has been most rigorously validated, this dosing is not practical for outpatient procedures. For high-risk patients undergoing elective outpatient procedures, similar total volumes of isotonic fluid composed of either saline or sodium bicarbonate, administered over shorter intervals may provide a more practical alternative, although this approach has not been formally tested against more prolonged durations of i.v. fluid administration. Further research into the optimal dose and timing of i.v. fluid administration, particularly for outpatients, is clearly needed. Intravenous fluid administration should not be eschewed in patients with a history of congestive heart failure. Rather, careful volume expansion should be accompanied by close vigilance for signs or symptoms of pulmonary compromise.
Although the benefit associated with NAC remains debatable, this agent has minimal toxicity and is inexpensive. Therefore, we recommend the use of oral NAC at a dose of 1200 mg twice daily on the day prior to and day of contrast administration. The use of NAC should not, however, provide a false sense of protection, and should not obviate good judgment in the decision to proceed with procedures that utilize intravascular radiocontrast. Nor should this medication be used in lieu of proven preventive interventions such as isotonic i.v. fluids. Agents that have been shown to be ineffective, and in some cases appear to be deleterious, such as mannitol, dopamine and fenoldopam, should not be utilized. Until large clinical trials shed further light on the role of atrial natriuretic peptide, statins, and prostaglandin analogs, we do not recommend their use. Similarly, we believe there is currently no role for prophylactic renal replacement therapy for the prevention of CIAKI.
Monitoring of renal function following the administration of iodinated radiocontrast is also important. We recommend that at a follow-up SCr should be obtained 48-72 h following the contrast administration in all high-risk patients.
Conclusion
Contrast-induced acute kidney injury is a common, yet potentially preventable iatrogenic condition. Prevention of CIAKI involves the identification of patients at increased risk, consideration of alternative imaging procedures that do not involve the administration of iodinated contrast, discontinuation of potentially nephrotoxic medications, administration of isotonic i.v. fluid, and, despite conflicting data on its efficacy, provision of high dose N-acetylcysteine. Large-scale, adequately powered trials are needed to better define the role of certain preventive interventions.
